Vaxcyte, Inc. (NasdaqGS: PCVX)
Health Care · Biotechnology · US
$62.46
+0.95% today · +103.2% 1Y
Vaxcyte, Inc. (NasdaqGS: PCVX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $9.21B and employs 507 people.
Over the last twelve months the share price has gained 103.2%, trading between 29.87 and 65.00.
Tweenvest scores Vaxcyte, Inc. across four factors: quality 28/100. Its strongest factor is quality.
PCVX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $9.21B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -7.65
- Dividend yield
- —
- Beta (5Y)
- 1.21
- 52-week high
- $65.00
- 52-week low
- $29.87
- Avg volume (3M)
- —
- Shares outstanding
- 148.81M
- Employees
- 507
- Next earnings
- —
About Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
- ISIN
- US92243G1085
- Founded
- 2013
- Listed since
- Jun 12, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.06 | +0.58% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.83 | +0.22% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $147.79 | +0.72% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $553.28 | +1.04% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $835.32 | +0.82% |
| argenx SEENXTBR: ARGX | $63.06B | €877.40 | +1.53% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.91 | +14.41% |
Figures last refreshed Aug 18, 2026.